Skip to main content
. Author manuscript; available in PMC: 2010 Nov 2.
Published in final edited form as: Am J Med Genet A. 2006 Apr 1;140(7):785–789. doi: 10.1002/ajmg.a.31142

TABLE IV.

PEMT Met212Val and Val95Ile Compound Genotype, Maternal Choline Intake, and Risk of Spina Bifida

Combined genotype Cases (%) Control (%) OR (95% CI)
Overall
 Met212/Met212 + Val95/Val95 10 (10.3) 30 (9.1) Referent
 Met212/Met212 + Val95/Ile95 18 (18.6) 73 (22.2) 0.74 (0.31–1.79)
 Met212/Met212 + Ile95/Ile95 10 (10.3) 37 (11.3) 0.81 (0.30–2.20)
 Met212/Val212 + Val95/Val95 18 (18.6) 64 (19.5) 0.84 (0.35–2.05)
 Met212/Val212 + Val95/Ile95 25 (25.8) 71 (21.6) 1.06 (0.45–2.47)
 Met212/Val212 + Ile95/Ile95 6 (6.2) 5 (1.5) 3.60 (0.90–14.39)
 Val212/Val212 + Val95/Val95 9 (9.3) 40 (12.2) 0.68 (0.24–1.87)
 Val212/Val212 + Val95/Ile95 1 (1.0) 9 (2.7) 0.33 (0.04–2.97)
 Val212/Val212 + Ile/95/Ile95 0 0
Lower 25% percentile
 Met212/Met212 + Val95/Val95 4 (12.9) 9 (11.0) Referent
 Met212/Met212 + Val95/Ile95 6 (19.4) 18 (22.0) 0.75 (0.17–3.35)
 Met212/Met212 + Ile95/Ile95 2 (6.5) 9 (11.0) 0.50 (0.07–3.45)
 Met212/Val212 + Val95/Val95 6 (19.4) 17 (20.7) 0.79 (0.18–3.56)
 Met212/Val212 + Val95/Ile95 6 (19.4) 17 (20.7) 0.79 (0.18–3.56)
 Met212/Val212 + Ile95/Ile95 3 (9.7) 1 (1.2) 6.75 (0.53–86.56)
 Val212/Val212 + Val95/Val95 4 (12.9) 9 (11.0) 1.00 (0.19–5.29)
 Val212/Val212 + Val95/Ile95 0 2 (2.4)
 Val212/Val212 + Ile/95/Ile95 0 0
Higher 25% percentile
 Met212/Met212 + Val95/Val95 6 (9.1) 21 (8.5) Referent
 Met212/Met212 + Val95/Ile95 12 (18.2) 55 (22.3) 0.76 (0.25–2.30)
 Met212/Met212 + Ile95/Ile95 8 (12.1) 28 (11.3) 1.00 (0.30–3.32)
 Met212/Val212 + Val95/Val95 12 (18.2) 47 (19.0) 0.89 (0.30–2.70)
 Met212/Val212 + Val95/Ile95 19 (28.8) 54 (21.9) 1.23 (0.43–3.51)
 Met212/Val212 + Ile95/Ile95 3 (4.6) 4 (1.6) 2.63 (0.46–15.11)
 Val212/Val212 + Val95/Val95 5 (7.6) 31 (12.6) 0.57 (0.15–2.09)
 Val212/Val212 + Val95/Ile95 1 (1.5) 7 (2.8) 0.50 (0.05–4.90)
 Val212/Val212 + Ile/95/Ile95 0 0
 Val212/Val212 + Ile/95/Ile95 0 0